Portal de Periódicos da CAPES

Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results From a Phase I/II Clinical Trial

2016; Elsevier BV; Volume: 175; Linguagem: Inglês

10.1016/j.ajo.2016.11.020

1879-1891

Richard A. Lewis, William C. Christie, Douglas G. Day, E. Randy Craven, Thomas R. Walters, Marina Bejanian, Susan S. Lee, Margot L. Goodkin, Jane Zhang, Scott M. Whitcup, Michael R. Robinson, Tin Aung, Allen D. Beck, William C. Christie, Michael Coote, Charles J. Crane, E. Randy Craven, Andrew Crichton, Douglas G. Day, F. Jane Durcan, William J. Flynn, Sébastien Gagné, Damien F. Goldberg, Delan Jinapriya, C. Starck Johnson, Shimon Kurtz, Richard A. Lewis, Steven L. Mansberger, Shamira Perera, Michael H. Rotberg, Robert M. Saltzmann, Howard I. Schenker, Michael Tepedino, Maria Imelda R. Yap-Veloso, Harvey S. Uy, Thomas R. Walters,

Ocular Surface and Contact Lens

PurposeTo evaluate the safety and intraocular pressure (IOP)-lowering effect of a biodegradable bimatoprost sustained-release implant (Bimatoprost SR).DesignPhase I/II, prospective, 24-month, dose-ranging, paired-eye controlled clinical trial.MethodsAt baseline following washout, open-angle glaucoma patients (n = 75) were administered Bimatoprost SR (6 μg, 10 μg, 15 μg, or 20 μg) intracamerally in the study eye; the fellow eye began topical bimatoprost 0.03% once daily. Rescue topical IOP-lowering medication or a single repeat treatment with implant was allowed. The primary endpoint was IOP change from baseline. The main safety measure was adverse events. Results through month 6 are reported.ResultsBimatoprost SR provided rapid, sustained IOP lowering. Overall mean IOP reduction from baseline through week 16 in study eyes was 7.2, 7.4, 8.1, and 9.5 mm Hg with the 6-μg, 10-μg, 15-μg, and 20-μg dose strengths of implant, respectively, vs 8.4 mm Hg in topical bimatoprost-treated pooled fellow eyes (data censored at rescue/retreatment). Rescue/retreatment was not required in 91% and 71% of study eyes up to week 16 and month 6, respectively. Adverse events in study eyes usually occurred within 2 days after the injection procedure and were transient. Conjunctival hyperemia with onset later than 2 days after the injection procedure was more common with topical bimatoprost than Bimatoprost SR (17.3% vs 6.7% of eyes).ConclusionsBimatoprost SR demonstrated favorable efficacy and safety through 6 months. All dose strengths were comparable to topical bimatoprost in overall IOP reduction through week 16. A single administration controlled IOP in the majority of patients for up to 6 months.